Provided by Tiger Trade Technology Pte. Ltd.

bioAffinity Technologies, Inc.

4.73
+2.0073.26%
Post-market: 4.55-0.1800-3.81%16:49 EDT
Volume:64.14M
Turnover:293.03M
Market Cap:21.28M
PE:-0.55
High:5.38
Open:2.78
Low:2.78
Close:2.73
52wk High:46.53
52wk Low:0.6930
Shares:4.50M
Float Shares:3.40M
Volume Ratio:2.02
T/O Rate:1885.63%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.6630
EPS(LYR):-8.6630
ROE:-301.83%
ROA:-75.63%
PB:2.92
PE(LYR):-0.55

Loading ...

Why Is bioAffinity Technologies Stock Surging Tuesday?

Benzinga_recent_news
·
Mar 17

bioAffinity Technologies releases CyPath Lung case study highlighting 92% sensitivity in nodules under 20 mm

Reuters
·
Mar 17

BUZZ - US STOCKS ON THE MOVE-Kyivstar Group, Applied Materials, Tevogen Bio

Reuters
·
Mar 14

bioAffinity Technologies Stock Soars 120% On CyPath Lung Sales Growth

Benzinga
·
Mar 13

bioAffinity Technologies FY2025 net loss widens 66% to USD 14.91 million on revenue down 34% to USD 6.16 million

Reuters
·
Mar 13

bioAffinity Technologies Announces Record 2025 Revenue and Unit Sales for Flagship Lung Cancer Diagnostic Cypath® Lung

THOMSON REUTERS
·
Mar 13

BioAffinity Technologies initiates clinical study for CyPath Lung

TIPRANKS
·
Mar 10

bioAffinity Technologies Announces Initiation of Large-Scale Longitudinal Clinical Study for Its Noninvasive Cypath® Lung Cancer Diagnostic

THOMSON REUTERS
·
Mar 10

bioAffinity Technologies directors Robert Anderson and Roby Joyce to step down at April 30 annual meeting

Reuters
·
Mar 07

bioAffinity Technologies reports positive findings for asthma therapy-matching sputum diagnostic platform

Reuters
·
Mar 03

BRIEF-Bioaffinity Announces Validation Study For Lung Cancer Test

Reuters
·
Feb 25

bioAffinity Technologies Partners With Brooke Army Medical Center on CyPath Lung Validation Study

Reuters
·
Feb 25

bioAffinity Technologies Announces Validation Study With Brooke Army Medical Center to Expand SAMPLE Collection Options for the Cypath® Lung Noninvasive Early Detection Lung Cancer Test

THOMSON REUTERS
·
Feb 25

bioAffinity Technologies Highlights CyPath Lung Case Study Supporting Noninvasive Lung Cancer Surveillance

Reuters
·
Feb 20

bioAffinity Technologies Showcases CyPath Lung Test Clinical Utility in Real-World Case Study

Reuters
·
Feb 17

BioAffinity Technologies announces new appointments to Advisory Board

TIPRANKS
·
Feb 09

bioAffinity Technologies Expands Advisory Board With Leading Lung Cancer Experts

Reuters
·
Feb 09

bioAffinity Technologies’ Precision Pathology Laboratory Services Maintains CAP Accreditation

Reuters
·
Jan 07

bioAffinity Technologies' Precision Pathology Laboratory Services Finalizes Succession with Dr. Humphreys as New Owner

Reuters
·
Dec 23, 2025

bioAffinity Technologies Showcases CyPath Lung Test Success in Early Lung Cancer Detection at NLCRT

Reuters
·
Dec 03, 2025